Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Dan Oliver, Ji Hyun Lee

09 April 2025

Register

When does outsourcing autologous collection center qualification and the cell therapy supply chain make sense?

Amy Hines, Jeni Newman, Marcel van Houten

14 November 2024

Watch

iPSC-based therapy dilemmas explored: overcoming hurdles for future success

L Munsie, K Raineri, M Carpenter et al

05 March 2024

Watch

Empowering the future of cell therapy: leveraging partnerships to support advancement

J Patarroyo, F Mack, X de Mollerat du Jeu et al

21 September 2023

Watch

Early-stage considerations for accelerating cell and gene therapy commercialization

Sabrina Carmichael

11 July 2023

Watch

How reducing labor time can save on your cell therapy manufacturing costs

Yen Kong, Jeeheon Kang, Janôt Schoep

21 June 2023

Watch

How can the gene therapy industry drive down the cost of goods to better serve patients?

Emmanuelle Cameau

13 June 2023

Watch

Commercializing cell and gene therapies: Navigating complex commercial readiness hurdles for a successful product launch

Andrea Briggs

09 May 2023

Watch

Improve your speed to therapy and drive efficiency by integrating supply chain and manufacturing

Robert Lutskus, Matthew Lakelin

21 March 2023

Watch

Driving the expansion of mRNA into the therapeutic sphere

Alejandro Becerra, Andreas Kuhn, Metin Kurtoglu

23 February 2023

Watch

Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19 mRNA vaccine approvals

S Zobbi, V Indurthi PhD, C Kröner et al

22 April 2021

Watch

Addressing the critical bottlenecks in the cell & gene therapy manufacturing pathway

P Zandstra, D Baksh, K Roy et al

21 June 2017

Watch

Automation of cell & gene therapy manufacture: challenges, options & opportunities for innovation

Q Rafiq, B Hanrahan, B Mistry et al

07 December 2016

Watch